Pathogens attempt to evade immune recognition by expressing mutated antigens. The present study shows that two mechanisms happen in vivo during the course of HIV infection to limit the escape of antigenic variants from cytotoxic T lymphocyte (CTL) recognition: recognition of several epitope variants by the same TCR and generation of several CTL populations specific for a single epitope but recognizing different variant sequences. We have studied two CTL populations directed towards the HIV-p24 gag amino acids 176-184 QASQEVKNW epitope, presented by HLA-B5301. Both CTL populations were derived from a long-term asymptomatic HIV-infected child and they express different TCR. Each of the two CTL recognizes five of the 10 naturally occurring variants. These variants are distinct for both CTL and thus a total of eight variants are recognized. Thus, polyclonality of CTL specific for the same epitope but differing in variant sequences recognized may improve the control of variant viruses' replication in vivo. In addition to cross-recognition of several variant epitopes, promiscuous recognition of exogenous peptides complexed to allogeneic HLA-B molecules occurs, showing that the TCR can tolerate amino acid changes on both the peptide and the MHC molecule. This flexibility of the TCR is probably of great importance for control of viruses with high genetic variability, such as HIV.
Introduction
In many viral infections, the immune system contains or vaccine development. X-ray analyses of MHC crystals have given important information on the function of MHC molecules eradicates the infectious agent. Numerous studies have shown that this is achieved at least in part by cytotoxic T as peptide receptors (6) . Biochemical isolation and studies of naturally MHC-associated peptides have determined peptide lymphocytes (CTL). High frequencies of CTL have been detected in HIV-infected subjects and there is accumulating ligand specificity of HLA class I allelic products (7) . Several apparently unrelated MHC allelic products are characterized evidence for a beneficial role of HIV-specific CTL in natural infection (reviewed in 1). Recently, both transfer of virusby strikingly similar specificities in terms of the main anchor residues of their peptide ligands. This observation and quantitspecific CTL and depletion of CD8 ϩ T lymphocytes have provided direct demonstration for the antiviral effect of CD8 ϩ ative binding assays have shown that several HLA alleles can be grouped in a single functional HLA supertype (8) . T cells in vivo in HIV and SIV infections (2-4). It is now widely accepted that an effective vaccine against HIV should elicit Knowledge of peptide ligand characteristics has improved the efficiency in definition of new CTL epitopes (9) . In addition, virus-specific CTL (5) .
CD8 ϩ CTL recognize virus-infected cells by an interaction they explain the promiscuity and degeneracy of CTL epitopes. The promiscuous recognition phenomenon refers to T cells between the TCR and a viral peptide presented by MHC class I molecules on the surface of the infected cells. Definition that bear TCR recognizing a given peptide complexed with different MHC molecules (10) . The capacity of a peptide of a pathogen's sequences recognized by CTL is critical for to bind multiple MHC molecules and, consequently, to be Table 1 . Sequence of the variants of CTL epitope p24 amino acids 176-184 used in this study immunogenic in the context of individuals from different MHC types has been referred to as degeneracy (10) .
A high rate of mutations is a characteristic feature of HIV. Epitope variation can result in the lack of antigen recognition or in the induction of an altered response to the pathogen. amino acid substitutions, as well as promiscuous recognition b These sequences are based on HIV Molecular Immunology Database (18) . Amino acids differing from the index sequence (26- of the same peptide complexed to different MHC molecules.
176) are underlined.
The clonality of CTL specific to a single viral peptide has been studied in various viral infections by determination of the TCR α and β chain usage or sequence. Most CTL responses to a single epitope are polyclonal, whereas some are highly oligoclonal. As TCR specific for the same peptide pression (CDC stage A2) and his viral load was Ͻ10 4 HIV RNA copies/ml. can contact different residues of the antigenic peptide, they may have different susceptibility to amino acid variations in Viruses and synthetic peptides this peptide (16) . The present study shows that the CTL response can prevent some immune escape by the flexibility Peptides corresponding to the naturally occurring variants of the QASQEVKNW epitope (18) were synthesized by Neosysof the TCR and by the polyclonality of CTL populations.
We have characterized two different CTL populations from tem (Strasbourg, France) and obtained through Agence Nationale de la Recherche sur le SIDA (Table 1) . The recomthe same long-term asymptomatic HIV-infected patient, that recognized an HLA-B5301-restricted epitope from HIVp24 gag binant vaccinia viruses (rVV) were provided by Transgè ne (Strasbourg, France) and were described in a previous study protein, amino acids 176-184 QASQEVKNW. These two CTL represent unique material as they were generated in the same (17) . VV-GAG-B encodes p55 gag from HIV Lai (vvTG1144) and VV-GAG-A encodes p55 gag from a clade A isolate HIV 92UG037 genetic background, during the course of a natural human infection, and they expressed distinct TCR that recognized (vvTG6026). the same epitope. Our results show the ability of the TCR Cell lines and media to recognize several epitope variants as well as peptides complexed to allogeneic molecules. In addition, the specificiEpstein-Barr virus-transformed B lymphoblastoid cell lines (EBV-B) derived from peripheral blood mononuclear cells ties of two CTL populations for variant peptides are clearly distinct. Thus both the flexibility of each TCR and the presence (PBMC) by standard techniques were maintained in RPMI 1640 (Whittaker, Gagny, France) supplemented with 2 mM of several CTL populations specific for a single epitope are advantageous for the infected host as they broaden the L-glutamine (Gibco/BRL, Cergy-Pontoise, France) and 10% FCS (Dutscher, Brumath, France) (RPMIc). WIE cell line was number of mutant epitopes recognized. a kind gift from Dr D. Schendel (Munchen, Germany). C1R cells were grown in RPMIc supplemented with 150 µg/ml Methods Hygromycin B (Coger, Paris, France). C1R cells transfected with HLA-B5301 were a kind gift from Dr Masafumi Takiguchi Patient (University of Kumamoto, Japan). CD8 ϩ T cells were cultured in RPMI 1640 supplemented with 5% human AB serum (ETS, Patient EM47 has been followed at Hô pital Necker (Paris, France). The legal guardians gave inform consent before Les Ulis, France), 2 mM L-glutamine, non-essential amino acids (Gibco/BRL), 1 mM sodium pyruvate (Gibco/BRL) and entering the study. This patient was born from an HIV-infected mother. He carried a clade B HIV subtype (17) . At time of 100 IU/ml rIL-2 (Chiron, Suresnes, France; a generous gift from Dr Lebour). Genotyping of EBV-B lines was performed isolation of CTL 141, he was 10.6 years old, had 582 CD4 ϩ / mm 3 , 1635 CD8 ϩ /mm 3 and his plasma viral load was Ͻ10 4 by Dr F. Gotch (Chelsea and Westminster Hospital, London, UK) using amplification refractory mutation system PCR. HIV copies/ml. He was in CDC stage A and untreated. At the time of isolation of CTL 977, he was 13.6 years old, had 340
Isolation of HIV-1-specific CTL clones CD4 ϩ /mm 3 , 1054 CD8 ϩ /mm 3 and his plasma viral load was 4ϫ10 3 HIV RNA copies/ml. He was in CDC stage A, and had CTL clones were obtained by seeding PBMC in limiting dilution and peptide-specific stimulations. Isolation of CTL received AZT and didanosine for 18 months. At 16 years of age, he was still asymptomatic, had no severe immunosupclone 141 was previously described (19) . Isolation of CTL using the same technique (19) . They were maintained by stimulations every 2-3 weeks. Autologous EBV-B cell lines were incubated overnight with index peptide at 100 ng/ml, then washed and irradiated (100 Gy). The stimulator to effector ratio was 1:1 and allogeneic irradiated feeder cells were added at a concentration of 10 6 cells/ml. A panel of TCR V β -specific antibodies previously used to stain the V β 13 ϩ CTL 141 (19) did not react with CTL 977, providing direct evidence that both TCR were distinct.
Cytotoxic assays
CTL assays were conventional 4-h 51 Cr-release assays as previously described (17) . EBV-B cells were infected with rVV 16 h before the assay, labeled for 1 h with 3.7 MBq of Na 2 51 CrO 4 (NEZ030; NEN, Le Blanc Mesnil, France), washed 3 times and used as target cells. For peptide assays, target cells were labeled for 1 h with Na 2 51 CrO 4 , washed and synthetic peptides were added just before mixing target cells and effector cells. Target cells (5ϫ10 3 ) were incubated in triplicate with effector cells, at various E:T ratios, in roundbottom 96-well plates, in 200 µl RPMIc supplemented with 10 mM HEPES (Gibco/BRL). The plates were incubated at 37°C for 4 h and then centrifuged at 150 g for 5 min. Next, 50 µl of supernatant from each well was mixed with 100 µl of scintillation liquid (81150401; Perkin-Elmer, Evry, France) and 51 Cr was measured in a β-counter (Microbeta 1450; PerkinElmer). Maximal release was obtained from targets lysed by 5% Triton X-100 ϩ 1% SDS. Spontaneous release was 
discarded. Percent specific lysis was calculated as
Percentages of specific lysis at an E:T ratio of 3:1 are presented.
100ϫ(experimental release -spontaneous release)/(maximal release -spontaneous release). The CTL responses against the HIV antigens were considered positive if they exceeded peptides 25-17B, 25-17A, 25-17D, 25-17M1 and 25-17M3. In the mean of control target lysis by 3 SD and by at least 10%.
contrast, CTL 977 recognized consensus clade A sequence EC 50 (50% effective concentration) is defined as peptide much more efficiently than the consensus clade B sequence concentration required to obtain 50% of maximal lysis.
(EC 50 were 0.18 and 47.5 ng/ml for peptides 25-17A and 25-17B respectively (18) . The sequences corresponded to optimal epitope as truncated 977 ( Fig. 3A and B) . Secondly, both effectors recognized with similar efficiency EBV-B cell line EM59 (B5301 ϩ C0401 -) and peptides were not recognized (data not shown). The two specific CTL populations recognized a different set of variant EBV-B cell line EM17 (HLA-B5301 ϩ HLA-C0401 ϩ ) ( Fig. 3C  and D) . These experiments strongly suggest that HLA-B5301 sequences ( Fig. 1A and B) . Peptide titration curves revealed that CTL 141 preferentially recognized the sequence correswas the restricting element of CTL 141 and 977. However, C1R cells and WIE EBV-B cells that expressed ponding to the clade B consensus, followed by clade A consensus sequence and minor variants ( Fig. 2A) . The HLA-B3501 and C0401, but not HLA-B5301, were lysed by effectors when pulsed with peptides ( Fig. 3A-D) . Recognition respective EC 50 were 0.18, 4.8, Ͼ1000, 599 and 56 ng/ml for of WIE cells, homozygous for HLA-B3501, was clearly reduced sented the peptides with efficiency that varied from 27 to 84% of autologous cell recognition for CTL 141 and 30 to 63% for for CTL 977, whereas they were well recognized by CTL 141. For CTL 141 EC 50 of index peptide 25-17B was only 10 times CTL 977. Lysis by CTL 141 of the HLA-B3501 ϩ WIE cell line was similar to that of the HLA-B3502 ϩ EM105. However, higher higher on WIE than on autologous EM47 EBV-B cells. In contrast, when rVV were used to endogenously express the epilysis of the HLA-B3502 ϩ cell line was observed with CTL 977 (Fig. 5 and Table 2 ). Lysis of the HLA-B3503 ϩ EM109 cell tope, C1R cells transfected with HLA-B5301 ϩ were efficiently recognized by both CTL but not the parental C1R cells that line by both CTL was very low. As both EM105 and EM109 expressed the HLA-B4901 molecules, differences in peptides are HLA-B3501 ϩ (Fig. 4A-F) . What is more, EM17 cells (HLA-B5301 ϩ ) but not WIE cells (HLA-B3501 ϩ ) were able to present presentation were probably due to the HLA-B35 allele. Thus, the various HLA-B35 subtypes have different ability to present the endogenously synthesized epitope to CTL (Fig. 4G-L) . From these results, we conclude that HLA-B5301 was the the peptides to CTL and the two CTL populations differ in their ability to recognize peptides presented by closely related HLArestricting molecule presenting p24 gag amino acids 176-184 CTL epitope to both CTL, 141 and 977. Presentation of exogen-B35 allelic variants. ous peptides by WIE or C1R cells may be viewed as promiscuMembers of the HLA-B7 supertype differed widely in their ous presentation of the peptides by HLA-B3501. Indeed, HLAability to present the p24 gag amino acids 176-184 CTL epitope B3501 and B5301 molecules are very similar and differ from each other by only 5 amino acids (20) (21) (22) .
For all target cells tested, lysis by CTL was not due to allogeneic recognition, as cells incubated with peptide-free medium were Promiscuous presentation of p24 gag amino acids 176-184 CTL not lysed (data not shown). Most targets were recognized with epitope by HLA-B35 allelic variants low efficiency by both CTL (percent of lysis Ͻ40% of lysis of autologous cells and minimal peptide concentration to obtain The first observation of promiscuous presentation of the epitope by both HLA-B5301 and B3501 led us to search for other related significant lysis equal or Ͼ10 ng/ml, Fig. 5 and Table 2 ). Several members of the HLA-B7 supertype, that includes HLA-B5301, HLA-B molecules able to present the antigenic peptides to both CTL populations. More than 30 EBV-B cell lines of known HLA were poorly recognized, such as HLA-B51, -B52, -B55 and -B7801 (see cell lines EM3, EM71, EM40, EM68, EM82 and genotype were tested for lysis by both 141 and 977 CTL at high peptide concentration (1 µg/ml; Fig. 5 ). For some targets, data EM98 in Fig. 5 and Table 2 ). Three cell lines had intermediate ability to present the peptide to both CTL: EM20 (HLA-B7, -were confirmed by testing 10-fold peptide dilutions and presentation of endogenously synthesized epitope (Table 2) . Lysis B50), EM60 (HLA-B0704, -B5601) and EM50 (HLA-B13, -B45). EM107 (HLA-B7, -B15) presented peptide with intermediate of the five HLA-B5301 ϩ cell lines was close to that of autologous cells (Fig. 5) . Minimal peptide concentration giving significant efficiency to CTL 141 only. Three of these cell lines expressed HLA-B7 that belongs to the same supertype family as HLA-B35 lysis was 0.1 ng/ml and only the HLA-B5301 ϩ matched cell lines presented endogenous peptide (Table 2) . These data and -B5301 (23). However, HLA-B7 ϩ cell lines differed in their ability to present the peptide to CTL (compare lysis of EM20, confirmed previous results and showed that HLA-B5301 was the most efficient HLA-presenting molecule, and the only one EM26, EM40 and EM60 in Table 2 and Fig. 5 ). These results may be due to HLA-B7 subtype-specific presentation, similar to able to present endogenously synthesized epitope.
Next, we observed that several HLA-B35 ϩ target cells prethat observed with the various HLA-B35 subtypes. Alternatively, they may be due to the second HLA-B allele expressed by the restricted CTL line (25) but not to the CTL described here. The HLA-B57 ϩ cell line EM3 coated with exogenous peptide or HLA-B7 ϩ cell line. Indeed B5601 carried by cell line EM60 also belongs to the HLA-B7 supertype (24) , but the second HLAinfected with rVV expressing Gag was lysed by autologous HLA-B57-restricted CTL (26), but not by HLA-B5301-restricted B56 ϩ cell line (Los 72) was poorly recognized. In conclusion, HLA molecules that belong to the same supertype as HLA-B53 CTL ( Fig. 5 and Table 2 ). In this case, promiscuous presentation to HLA-B5301-restricted CTL was not limited by ability of the varied widely in their ability to present the antigenic peptides to CTL 141 and 977. target cell to process, bind and present the epitope, but by the capacity of the TCR to recognize the peptide bound to Most of the target cells expressing HLA-B alleles unrelated to HLA-B53 were lysed with low efficiency. However, EM50
HLA-B57. Definitive conclusions on the ability of the HLA-B molecules (HLA-B13, -B45) cell line was able to present the peptides with moderate efficiency (Table 2) . Only one subtype has been to present the peptides will require additional experiments with cell lines transfected with a single, well-defined HLA molecule. described for HLA-B45. As the second HLA-B45 ϩ cell line tested (EM71) poorly presented the peptide, presentation by However, our experiments show that the pattern of HLA molecules recognized by a given TCR only partly matched the HLA the EM50 cell line was probably due to HLA-B13. Therefore, HLA molecules unrelated to HLA-B5301 or to the HLA-B7 molecules that share similar peptide binding motifs. In addition, the two distinct TCR differed in their pattern of promiscuous supertype, such as HLA-B13, could present the peptide to HLA-B5301-restricted CTL. On the contrary, HLA-B57 is able recognition of allogeneic HLA-B molecules complexed to the peptide. to present the same peptide, QASQEVKNW, to HLA-B57- 
Some epitope variants were presented with greater efficiency
was more efficient on an allogeneic HLA molecule than on the appropriate restricting element, whereas the opposite by HLA-B35 than by HLA-B5301 to CTL 141 phenomenon was observed for the index peptide, 25-17B. Promiscuous recognition of allogeneic target cells pulsed with index peptide is summarized in Fig. 5 . At the same time, variant peptides were also tested for recognition on a misDiscussion matched target cell line (data not shown). Results were always consistent with those obtained with the index peptide, except Two CTL populations specific for the same HIV epitope were isolated from a long-term asymptomatic child. They express in one case: HLA-B3501 ϩ cells presented variants peptides 25-17D, 25-17M1 and 25-17M3 more efficiently than autologdifferent TCR and recognize distinct variants of the epitope. These CTL are tolerant to mutations on the antigenic peptide ous HLA-B5301 ϩ target cells to CTL 141. This phenomenon was confirmed by peptide titration (Fig. 6 ). 25-17D and 25-and amino acids variations on the HLA-B-presenting molecule. This study shows that both the flexibility of the TCR and the 17M1 peptide concentrations were 1000 times lower on the WIE HLA-B3501 ϩ cell line than on the autologous HLApolyclonality of the CTL response broaden the number of mutant viral sequences recognized by the immune system. B5301 ϩ cell line to reach similar lysis. For peptide 25-17M3, lysis was slightly enhanced on the HLA-B3501 ϩ cell line Thus both mechanisms may avoid the immune escape of HIV variants in vivo. (Fig. 6 ) and peptide 25-17A was presented with similar efficiency (data not shown). This experiment shows that for
We describe here an HLA-B5301-restricted CTL epitope, QASQEVKNW from HIV-p24 gag . This epitope does not fit the one of the two CTL populations, recognition of variant peptides HLA-B5301 peptide-binding motif. The initial description of B7 supertype and with structural characteristics of the HLA-B5301 peptide binding groove. the HLA-B3501 and -B5301 peptide binding by pool sequencing of self-peptides eluted from the molecules proposed Some peptides are immunogenic in the context of different MHC molecules. Such degenerate immunogenicity of CTL proline as the only amino acid found at position 2 for both molecules (27) . Later, the presence of P, A and V at position epitope presented in the context of multiple MHC alleles was described for HLA-A3 and -A11 (10), for distinct HLA-A2 2 was reported for peptides binding to HLA-B3501 (28) , and A at position 2 was found for most HLA molecules from the subtypes (30), for HLA-B35 and -B51 (31,32). The p24 gag amino acids 176-184 CTL epitope described here was B5 family (29). As HLA-B3501 and -B5301 share the same B pocket, the presence of A instead of P in position 2 in some reported to be presented in the context of HLA-B5701 (25) . Thus, our study identified another degenerate CTL epitope. HLA-B5301-binding peptides is not unexpected. Furthermore, the crystal structure of HLA-B5301 revealed a reduced volume Promiscuous presentation of CTL epitope by several MHC class I molecules to the same CTL clone was previously of the B pocket, which may tolerate the presence of the small alanine side chain (22) . Thus, the presence of A in position reported in infectious and cancer diseases. On the contrary, minor differences between two MHC molecules can pro-2 of the epitope p24 gag amino acids 176-184 does not fit with the peptide binding motif proposed for HLA-B5301 (27) , but foundly affect recognition by the TCR. Several examples of both situations have been described for HIV-specific CTL. is consistent with peptide binding characteristics of the HLA- EM3  A1  A2  B51  B57  C6  C16  1  10  --Los 72  A1  A24  B8  B56  C3  C7  100  100  ND a  ND a  EM98  A23  A33  B49  B78  C0701  C1601  100  10  ND a  ND a  EM71  A1  A2  B45  B51  C6  C15  1-10  100  --EM95  A30  A68  B8  B62?  C4  C0701  100  10  --EM97  A34  A68  B13  B62  C18  C18  10  10  --EM63  A2  A2  B1801  B4402  C0501  C0702  100  1000  ND a  ND a  EM50  A2  A29  B13  B45  C6  C16  1  1  --EM45  A2  A0301  B1401  B39  C0802  C1213  100  1000 ND a ND a a Not done. Some but not all HLA-B3501 CTL epitopes can be presented by HLA-B5802 (25, 33) . In our study, addition of free exogenous peptide induced lysis of almost all cell lines tested, by HLA-B5101 (31) . CTL from HLA-B5701 ϩ patients recognized epitopes presented by HLA-B5701 and B5801, but not although the level of lysis depended on HLA molecules expressed by the target cell. The specificity of TCR recognition 17A and 25-17B were recognized by the CTL. Therefore, TCR promiscuous recognition of variant epitopes will not be limited was well illustrated by the differential recognition of three allelic variants of the HLA-B35 molecule. Our experiments by antigen processing, unless mutations directly affect binding to the HLA molecule or cleavage by the cellular proteases. allowed the assessment of the biological relevance of the HLA supertypes in the context of presentation of free exogenous
It is important to note that some variant peptides are recognized only at very high peptide concentration, such as peptide peptide to CTL. One main finding of the present study is that promiscuous presentation of the QASQEVKNW epitope did 25-17D by CTL 141. It is therefore probable that the level of endogenously processed peptide for this variant will be too not fully match the HLA-B7 supertype, to which HLA-B5301 belongs. As an example, the EM50 cell line, which expressed low to be recognized by this CTL. Our study showed promiscuous recognition of several HLA-B13 and B45 that are not related to the HLA-B7 supertype, was better recognized than some cell lines naturally occurring sequence variants by two CTL. These two CTL isolated from the same patient displayed only partially expressing HLA molecules related to the HLA-B7 supertype (see Fig. 5 ). Promiscuous recognition of the same epitope in overlapping patterns of variant sequence recognition. This observation supports the role of CTL polyclonality as a the context of different HLA molecules depends on the ability of the MHC to bind the peptide. The EM3 HLA-B57 ϩ cell line mechanism to broaden the recognition of various HIV subtypes and this may be particularly relevant for vaccine design bound, processed and presented the same peptide to HLA-B57-restricted CTL (26) . In this case, the low level of promiscuaimed at inducing CTL that recognize the various HIV strains present worldwide. They may have been generated at the ous presentation was not due to the binding capacity of the HLA molecule but rather to the specificity of the TCR. In same time or they may reflect sequential expansion of CTL specific for variants that have emerged over time (36). In conclusion, our data showed that the affinity of TCR for the MHC-peptide complex plays a major role in promiscuous addition, our results showed that TCR plasticity played a determinant role in promiscuous presentation of modified recognition of the antigenic peptide, independently of the peptide binding characteristics of the HLA molecule. This peptides or HLA molecules. In conclusion, both the flexibility of the TCR and the polyclonality of the CTL may be advantastudy shows that the TCR can tolerate modification of its ligand, either on the peptide or on the HLA molecule. This geous for the host, since they allow recognition of a different set of peptides by the infected host and may thus contribute adaptability may be relevant in vivo to recognize new viral variants.
to the limitation of viral immune escape by mutation of CTL epitopes. The resolution of crystal structures of three different MHC class I-restricted TCR complexed with their respective peptide-MHC ligands has revealed general features of the interAcknowledgements action of the TCR with their ligands (16, 34, 35) . For each of lines the two endogenously synthesized epitope variants 25-
